Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Has Consensus Target Price of $37.25 According to Analysts

Key Points

• Analysts rate Zai Lab a “Moderate Buy”, with four buy ratings, one strong buy, one hold and one sell among seven analysts; the average 12-month price target is $37.25.
• Zai Lab’s latest quarterly results beat estimates: loss per share was $0.41 versus the expected $0.59 loss, while revenue of $108.21 million slightly exceeded consensus.
• Several institutional investors increased or initiated positions in Zai Lab during the third quarter; hedge funds and other institutions collectively own 41.65% of its shares.

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $37.25.

A number of brokerages recently weighed in on ZLAB. Wall Street Zen upgraded shares of Zai Lab from a "sell" rating to a "hold" rating in a research note on Saturday, September 26th. Citigroup raised their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Zai Lab in a research note on Tuesday, October 27th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a report on Tuesday, October 6th.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Nan Fung Trinity HK Ltd. lifted its position in Zai Lab by 106.9% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company's stock worth $7,743,000 after acquiring an additional 151,883 shares during the period. Alps Advisors Inc. increased its holdings in shares of Zai Lab by 34.9% in the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company's stock valued at $3,924,000 after purchasing an additional 38,562 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Zai Lab in the third quarter valued at approximately $62,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zai Lab in the third quarter valued at approximately $211,000. Finally, WealthPlan Investment Management LLC purchased a new stake in shares of Zai Lab during the third quarter worth approximately $969,000. Hedge funds and other institutional investors own 41.65% of the company's stock.

Zai Lab Stock Down 0.0%

ZLAB opened at $26.42 on Thursday. Zai Lab has a 52 week low of $15.96 and a 52 week high of $29.02. The business's 50 day moving average is $24.67 and its two-hundred day moving average is $21.18. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -14.76 and a beta of 0.77.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.18. The business had revenue of $108.21 million during the quarter, compared to the consensus estimate of $107.90 million. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. Equities analysts expect that Zai Lab will post -2.19 EPS for the current fiscal year.

About Zai Lab

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab's portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.